1. The American College of Radiology (ACR) classifies gadolinium-based contrast agents (GBCAs) based on risk of inducing nephrogenic systemic fibrosis. Which Group of agents carries the highest risk?
A. Group I
B. Group II
C. Group III
D. Group IV
2. While gadolinium chelates at equilibrium are very stable, after injection they become diluted and try to ___________.
A. maintain chelation
B. cross the blood-brain barrier
C. reestablish equilibrium
D. disassociate
3. Rat studies by Frenzel et al demonstrated all of the following EXCEPT ____________.
A. GBCAs can indirectly cross the blood-brain barrier intact
B. macrocyclic GBCAs remain intact for at least 24 days
C. linear GBCAs do not remain intact when measuring them for a period of 24 days
D. GBCAs are cleared from the brain by diffusion and liver clearance
4. The majority of patients who developed nephrogenic systemic fibrosis (NSF) _______
A. were on dialysis
B. received several doses of gadolinium
C. had acute kidney injury or chronic kidney disease
D. all of the above
5. For inpatients undergoing a contrast-enhanced MRI with administration of a Group I/III agent, the 2017 ACR recommendation for obtaining an eGFR is within _______of the MRI.
A. 1 day
B. 2 days
C. 12 hours
D. 36 hours
6. For patients receiving a standard dose of a Group II GBCA, the 2017 ACR recommends assessment of renal function using _____.
A. eGFR
B. serum creatinine
C. BUN (blood urea nitrogen)
D. optional questionnaire
7. According to market research, ____ of the 3 million annual pediatric MRI exams performed in the USA are contrast-enhanced.
A. 20%
B. 30%
C. 40%
D. 50%
8. A study by Murata et al of tissue samples from the autopsies of 9 patients revealed the greatest amount of gadolinium deposition in _______.
A. skin
B. cortical bone
C. brain
D. breast
Evaluation Questions
9. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
10. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
11. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Will the information presented cause you to change your practice?
A. Yes
B. No
21. Are you committed to making these changes?
A. Yes
B. No
22. As a result of this activity, did you learn something new?
A. Yes
B. No
23. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
24. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
E. >20